Global 3D Printing Drug Market – Industry Analysis, Forecasts and Opportunity Assessment (2016-2023)

Report on Global 3D Printing Drug Market – Industry Analysis, Forecasts and Opportunity Assessment (2016-2023)

Introduction to Global 3D Printing Drug Market

3D Printed Drugs are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. 3D drugs differ from normal drugs in the way they are structured and in the ease of use. 3D drugs have unitary porous structures that readily disperse in the mouth, as a result of which these high-dose medicines are not swallowed intact. Such type of medication is helpful to patients who often have swallowing difficulties. 3D printed drug is still a novelty is the market and customers are largely unaware of existence of such drugs. The US is the biggest market for 3D printed drugs right now followed by UK. While the drugs tremendous advantage over traditional drugs, they are marred by various adversities as well. Some of them include adverse effect related to these drugs, usage of 3D printing to develop illegal drugs, and lack of government regulations, phishing and hacking of data.

Market Dynamics

3D printed drugs market is highly niche in current scenario and hence market is dominated by 1-2 players. One of the prominent 3D printed drugs being sold is Spritam which is the only 3D printed drug available in the market since 2016 to treat epilepsy.Although in its nascent stage, 3D printed drugs market is estimated to reach $278 million in 2018 and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. The market is banking on technological advancement and increased awareness to fuel the growth in future. US commands the highest market share for 3D printed drugs and expected to extend its market share further. Europe is estimated to account for more than 50% share in 2020 and is expected to dominate the market in forecasted future owing to presence of well-established healthcare systems and increase in prevalence of dysphagia. The European key players in 3D printed drug market are anticipated to take advantage of this growth. Asia-pacific market for 3D printed drugs is supposed to grow rapidly as well owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

Market segmentation

The 3D printed drug market can be segmented based on Geography, Scenario,and region.
By Geography:

  • US
  • Rest of the world

By Scenario:

  • Low growth scenario
  • Moderate growth scenario
  • Rapid growth scenario

By Region• North America – US, Rest of North America

  • Europe – UK, Germany, France, Italy, Spain, Rest of Europe
  • Asia-pacific – Japan, China, Australia, Rest of Asia Pacific
  • LAMEA – Brazil, Saudi Arabia, Rest of LAMEA

Opportunities

The 3D printed drugs are drugs of the future. There are millions of patients for whom swallowing a solid drug remains a challenge and for them, 3D printed drugs can be the alternative. 3D printed drugs are highly customizableand can be adjusted as per the needs of the patients. These advantages will put 3D printed drugs in the driver seat in few years and as the awareness will rise, market will further expand. The market is expected to grow at a CAGR of 6.5% in the next decade, giving an indication of rise in market penetration.

Key Players

Aprecia Pharmaceuticals
GlaxoSmithKline Plc.
Hewlett Packard Caribe
BV
LLC
3D Printer Drug Machine
FabRx Ltd.

The report contains a comprehensive analysis on:

  • Global 3D Printing Drug Market Segments
  • Global 3D Printing Drug Market Drivers, Restraints and Opportunities
  • Global 3D Printing Drug Market Size & Forecast 2016 to 2023
  • Supply & Demand Value Chain
  • Global 3D Printing Drug Market Current Trends
  • Competition & Major Companies
  • Technology and R&D Status
  • Porters Five Force Analysis
  • Strategic and Critical Success Factor Analysis of Key Players

Regional analysis for Global 3D Printing Drug Market includes:

  • North America
    • US and Canada
  • Latin America
    • Mexico, Brazil, Argentina and Rest of Latin America
  • Western Europe
    • EU5 (Germany, France, Italy, Spain, U.K.)
    • Nordic Countries (Denmark, Finland, Norway, and Sweden)
    • Benelux (Belgium, The Netherlands, and Luxembourg)
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Rest of Eastern Europe
  • Asia Pacific
    • Global
    • India
    • Japan
    • Australia and New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
    • South Africa
    • North Africa
    • Rest of Middle East and Africa

This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides in-depth market segmentation that is derived from extensive product mapping exercises, macroeconomic factors, and other qualitative and quantitative insights. The impact of all such factors is delivered across multiple market segments and geographies.

Report Highlights

  • Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
  • Consumer and Pricing Analysis
  • Market dynamics of the industry
  • In-depth Market Segmentation
  • Historical and Projected Market Sizing in terms of volume and value
  • Recent market trends and Impact Factors
  • R&D Status and Technology Overview
  • Extensive Industry Structure Coverage

 

Leave a Reply

Your email address will not be published.

×
Sample Report
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. You may contact us at any time to opt-out. Please tick here to receive these communications.
×
Report Customisation
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. You may contact us at any time to opt-out. Please tick here to receive these communications.
×